Orion Oyj A

ORNAV · Nasdaq Helsinki · Healthcare

80.40EUR −0.4%last day

Price as of 2 October 2026

The price over the past year, with dividends: +27.3%

Performance

1 month

+1.0%

1 year

+27.3%

3 years, per year

+33.7%

5 years, per year

+22.7%

Largest fall, 3 years

−35.7%

Below the peak now

−3.9%

Volatility, 1 year

33.1%

Return with dividends reinvested.

Key figures

P/E

19.0

P/B

8.8

Dividend yield

2.1%

Return on equity

+46.3%

Net margin

+28.5%

Market value

12.7 bn USD

Quality, value and trend

Where Orion stands against every Nordic stock today. 100 is best.

Quality98

Profitability and a sound balance sheet over time. Better than 98% of Nordic stocks.

Value20

The price measured against earnings, assets and cash flow. Better than 20% of Nordic stocks.

Trend83

The price development over the past year. Better than 83% of Nordic stocks.

Combined83

Quality, value and trend together. Better than 83% of Nordic stocks.

About Orion

Orion Oyj A is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 4,000 employees.

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis